One of the wonders of a new technology is that you just never know what uses will develop.
Here is an interesting customer for ILMN:
" Illumina believes its market is currently worth $3 billion, but the company is also well aware of the huge potential of broader sequencing use. There are already signs that consumers are starting to pick up on the value of genome sequencing, as CEO Jay Flatley pointed out a $7 million order from Ancestry.com (Nasdaq: ACOM ) . The fact that $7 million in consumer demand exists at this stage is a great sign, despite its relatively small present impact on revenue."
I'm quite sure that a few years ago the idea of a genealogy company placing an order with a gene sequencing company would probably have been met with a bit of skepticism, but here you have it happening.
This is indeed unexpected (for me). However, I am surprised that ancestry.com would use full genetic sequencing rather than one of the several much cheaper variants that are available for things like paternity tests. Furthermore, if there is one area where PACB is completely non-competitive at this point is high throughput low-cost (relatively) low-quality human genome re-sequencing.